Virtual Health Assistants Markets 2019: Investment Landscape, Clinical Evidence, and Regulatory Environment

News provided by

Jul 25, 2019, 12:00 ET

DUBLIN, July 25, 2019 /PRNewswire/ -- The "Virtual Health Assistants Report 2019" report has been added to ResearchAndMarkets.com's offering.

The report looks at the investment landscape, clinical evidence, and regulatory environment for VHAs, and also explores end-user feedback and case studies looking at both the positives and negatives of VHAs. This report is a go-to resource to understand and build individuals knowledge of the burgeoning virtual health assistant space in healthcare.

Commercial models are still nascent, the technology (AI) is premature, clinical evidence is sparse, integration into existing EMRs/health records is incomplete, and data security concerns exist. Despite all of this we explore if AI assistants rise above being "second-class concierge".

In the virtual+ AI combination space, think of reduced admin burden for HCPs, think of reduced consultation time and outpatient clinic time, think of an informed and engaged patient in control of their health and disease, think of a hospital whose beds are not full, think of an insurance plan that you understand clearly. The utopian world of healthcare in our minds could actually be reality if we do this right. This is huge.

Key Takeaways

End user perception
The willingness of consumer & clinicians to use VHA's
Adoption of VHA's to date
Commercial models are still nascent
The technology (AI) is premature
Clinical evidence is sparse
integration into existing EMRs incomplete
data security concerns
integrated part of healthcare delivery

Countries Covered:

UK
USA
India
UK
Germany
China
Australia

Audience

Anyone in the healthcare space interested in VHAs (HCPs, Start-Ups, Pharma, Payers, Big Tech, Patients, etc). Particularly interesting for those looking to integrate a VHA into their offerings like pharma or health systems.

Key Topics Covered:

1. INTRODUCTION & BACKGROUND

The Problem and The VHA Opportunity
Defining VHAs
Landscape Overview
VHA Use Cases

2. CONSUMER & CLINICIAN PERCEPTIONS

Consumer Survey Feedback - Awareness, Adoption, Trust
Clinician Survey Feedback - Awareness, Adoption, Trust

3. INVESTMENT & COMMERCIAL ACTIVITY

Investment Landscape
Commercial Activity

4. CLINICAL EVIDENCE & REGULATION

What Clinical Evidence exists for VHAs?
Framework for Risk Categorisation
Regulation of VHAs
Lessons from the AMA & NHS

5. CASE STUDIES

Babylon
The CareVoice
Amazon Alexa
Conversa

6. KEY TAKEAWAYS

7. EXPERT CONTRIBUTORS

Companies Mentioned

aiva
Amazon (Alexa)
AstraZeneca
Atrium Health
avaamo
Babylon
Boston Childrens hospital
bot4health
botmd
boundlss
Brigham Womens hospital
buoy
Bupa
care.coach
careangel
Catalia Health
Cedars Sinai
Centura Health
clevertar
Conversa
conversationHEALTH
corti
cuida
dr.sintomas
ELLI.Q
florence.chat
Gyant
Healthifyme
healthtap
IBM
infermedica
Izzy
kencor health
kiroku
Lark
Mayo Clinic
MDOps
mediktor
medwhat
memorylane
merit
next IT
NHS
Northwell Health
notable
Novo Nordisk
Nuance
orbita
pillo
Ping AN
ReminderRosie
robin
Samsung
saykara
sensely
Sensentia
sonde
Sopris Health
Suki
Sutter Health
Tenor.AI
Teva
The CareVoice
woebot
wysa
Your.MD

For more information about this report visit https://www.researchandmarkets.com/r/rx2qlo

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets